Aquestive Therapeutics (AQST) Other Non-Current Liabilities (2017 - 2026)

Aquestive Therapeutics' Other Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $6.1 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 172.9% year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $6.1 million (up 172.9% YoY), while the FY2025 annual figure was $7.3 million, up 203.51% from the prior year.
• Other Non-Current Liabilities was $6.1 million for Q1 2026 at Aquestive Therapeutics, down from $7.3 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $7.3 million in Q4 2025 to a low of $1.9 million in Q1 2022.
• Historically, Other Non-Current Liabilities has averaged $2.6 million across 5 years, with a median of $2.1 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities retreated 18.15% in 2022, then jumped 203.51% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $2.0 million in 2022, then slipped by 0.88% to $2.0 million in 2023, then climbed by 18.8% to $2.4 million in 2024, then surged by 203.51% to $7.3 million in 2025, then slipped by 16.73% to $6.1 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $6.1 million (Q1 2026), $7.3 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.